Senior Correspondent, London
Ben's Feed
Apr 14, 2014
Apr 13, 2014
Apr 13, 2014
Apr 13, 2014
Apr 11, 2014
Apr 11, 2014

Doctors welcome hepatitis C drug rivals, Gilead still leads

LOS ANGELES/LONDON (Reuters) – Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

Gilead, under fire from insurers and legislators for the $1,000-a-pill price of its Sovaldi drug, presented pivotal data on Friday at the European Association for the Study of the Liver conference in London, showing a cure rate of 94 percent after eight weeks of treatment with its experimental two-drug pill.

Apr 10, 2014

Hospira wins UK case to overturn patents on Roche drug Herceptin

LONDON (Reuters) – Hospira has successfully overturned two patents on Roche’s blockbuster breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

A ruling handed down by the High Court in London on Thursday determined that both the 115 and 455 patents on the drug, which relate to the drug’s dosage and its composition, were invalid.

Apr 9, 2014
Apr 9, 2014
Apr 9, 2014

WHO joins clamor to make new hepatitis C pills affordable

LONDON (Reuters) – The World Health Organization wants a “concerted effort” to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

The forthright comments from the UN agency on Wednesday add to pressure on drugmakers such as Gilead Sciences – which is already facing protests in the United States over its $1,000-a-day pill – to do more to improve access.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben